Literature DB >> 15070916

Adults with partial growth hormone deficiency have an adverse body composition.

Robert D Murray1, Judith E Adams, Stephen M Shalet.   

Abstract

The current biochemical definition of severe GH deficiency (stimulated peak GH < 3 micro g/liter) provides good separation of GH-deficient (GHD) adults from normal subjects, although it may not account for all patients with impaired GH secretion. The vast majority of normal subjects display a peak GH level in excess of 7 micro g/liter in response to the insulin tolerance test. Using a peak GH response of 7 micro g/liter as an arbitrary upper limit, we investigated the effects of partial GH deficiency (GH insufficiency, GHI; peak GH response of 3-7 micro g/liter) on the body composition of hypopituitary adults. GHD adults (n = 30, peak GH < 3 micro g/liter) were of shorter stature than the controls. Body mass index was not significantly increased, but waist/hip ratio (0.885 vs. 0.818, P = 0.001) and skinfold thickness (78.2 vs. 59.6 mm, P = 0.003) were greater than control subjects. Bioimpedance analysis revealed these patients to have reduced lean body mass (LBM) (44.4 vs. 51.2 kg, P = 0.023) and increased fat mass (FM) (25.7 vs. 18.4 kg, P = 0.039). Dual-energy x-ray absorptiometry (DXA) analysis of body composition confirmed reduced LBM (43.6 vs. 50.6 kg, P = 0.010) and increased FM (26.0 vs. 19.2 kg, P = 0.015). The excess FM was observed to be primarily truncal in distribution. Similarly, GHI adults were of shorter stature but with increased waist/hip ratio (0.871 vs. 0.818, P = 0.006) and skinfold thickness (80.8 vs. 59.6 mm, P = 0.003), compared with controls. Bioimpedance analysis revealed a reduction in LBM (44.9 vs. 51.2 kg, P = 0.020). DXA studies confirmed the reduced LBM (45.0 vs. 50.6 kg, P = 0.041) and additionally noted an increase in percent FM (32.9 vs. 27.4%, P = 0.019). All measures of body composition in the GHI patients were intermediate between those of the controls and GHD patients. Serum leptin levels were significantly elevated in both the GHD (41.5 vs. 20.7 ng/ml, P = 0.009) and GHI (36.7 vs. 20.7 ng/ml, P = 0.022) adults, compared with healthy controls. The excess FM observed using DXA in the GHD and GHI adults equated to 6.5 kg (8%) and 3.5 kg (5.5%), respectively, relative to healthy controls. In summary, we have shown that adults with GHI have abnormalities of body composition characteristic of GHD. The degree of abnormality of body composition lies between that of healthy subjects and GHD adults and correlates with the IGF-I level. Any future trials of GH replacement in patients with GHI must await further studies to establish the exact impact of this relative deficiency on the broad spectrum of biological end points influenced by GH status.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070916     DOI: 10.1210/jc.2003-030761

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Authors:  Jiajia Xia; Linman Li; Wei Ren; Xiaoya Zheng; Chan Liu; Jinchao Li; Tingying Chen; Xiaofeng Li; Lingli Wang; Yumei Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

3.  Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index.

Authors:  Carolina Di Somma; Alessandro Ciresi; Marco C Amato; Silvia Savastano; Maria Cristina Savanelli; Elisabetta Scarano; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

4.  Body mass index and blood glucose: correlations with serum insulin, growth hormone, and insulin-like growth factor-1 levels in patients with diffuse idiopathic skeletal hyperostosis (DISH).

Authors:  Charles W Denko; Charles J Malemud
Journal:  Rheumatol Int       Date:  2005-02-10       Impact factor: 2.631

5.  GH secretion reserve in subclinical hypercortisolism.

Authors:  Serena Palmieri; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Elisa Cairoli; Volha V Zhukouskaya; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

6.  Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications.

Authors:  Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  Int J Pept       Date:  2010-02-09

7.  The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.

Authors:  Justine Bacchetta; Katherine Wesseling-Perry; Beatriz Kuizon; Renata C Pereira; Barbara Gales; He-jing Wang; Robert Elashoff; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-04       Impact factor: 8.237

8.  Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults.

Authors:  Janet Lo; Sung M You; Jeffrey Wei; Bridget Canavan; Steven Grinspoon
Journal:  Clin Endocrinol (Oxf)       Date:  2009-04-17       Impact factor: 3.478

9.  Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels.

Authors:  Kevin C J Yuen; David M Cook; Prem Sahasranam; Pragnesh Patel; David E Ghods; Hrayr K Shahinian; Theodore C Friedman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-25       Impact factor: 3.478

Review 10.  The consequences of chronic kidney disease on bone metabolism and growth in children.

Authors:  Justine Bacchetta; Jérôme Harambat; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Nephrol Dial Transplant       Date:  2012-08       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.